Pacira settles EXPAREL patent litigation; Fresenius licensed to sell generic from early 2030

Pacira BioSciences, Inc.

Settlement with Fresenius Kabi, eVenus, Jiangsu Hengrui resolves all patent suits over EXPAREL (bupivacaine liposome).
Fresenius gets license to sell volume-limited generic starting on confidential date in early 2030, before last patent expiry in 2044.
Volume-limited percentages start at high-single-digit, increase to low-thirties in 2033, capped at high-thirties for final three years.
Unlimited generic license granted no earlier than 2039.
Pacira pays Fresenius $7 million for expected litigation cost savings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.